RxDoctor Payments Data

Joshua Eikenberg, MD

Dermatology · Roanoke, VANPI 1053708685

Payments from drug & device makers

$1,115in general payments, 2019–2025

Across 27 payments — averaging $41.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$590
  • Galderma Laboratories, L.p.$118
  • Pfizer$95
  • Amgen$80
  • Bristol Myers Squibb$65
  • Strata Skin Sciences, Inc.$53
  • plus $113 from 4 others

What the payments were for

  • Food & beverage$1,115100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,115 in reported general payments places this provider in the 40th percentile of 396 dermatology providers in Virginia.

See all dermatology providers in Virginia

Medicare billing

Part B allowed, 2024
$246,014
Medicare patients
507
Services billed
3,049

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab26$97,508
Taltz AutoinjectorIxekizumab14$97,009
OtezlaApremilast12$60,715
AdbryTralokinumab-Ldrm12$47,539
OpzeluraRuxolitinib Phosphate17$33,877
Tacrolimus90$21,305
Clobetasol Propionate140$8,271
Desonide38$3,191
Tretinoin44$2,694
Ketoconazole124$2,497
Calcipotriene12$2,366
Azelaic Acid35$1,962
Fluocinonide25$1,829
Triamcinolone Acetonide100$1,007
Imiquimod20$932

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$80$60,71512 claims
Incyte CorporationOpzelura$18$33,87717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 396 dermatology providers in Virginia.

Other dermatology in Roanoke

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →